Compositions and methods for modulating c-kit and PDGFR receptors

US7678792B2 · kind B2 · utility

Assignee

• IRM Inc. · BM

Inventors

• Donatella Chianelli · San Diego, US
• Christopher Cow · San Diego, US
• Yun He · San Diego, US
• Songchun Jiang · San Diego, US
• Xiaolin Li · San Diego, US
• Xiaodong Liu · Beijing, CN
• Zuosheng Liu · San Diego, US
• Jon Loren · San Diego, US
• Valentina Molteni · San Diego, US
• Juliet Nabakka · San Diego, US
• Pingda Ren · San Diego, US
• Taebo Sim · San Diego, US
• Xiaodong Wang · Zhejiang, CN
• Shuli You · Shanghai, CN

Key dates

• Filing date: Oct 16, 2007
• Grant date: Mar 16, 2010
• Expiry date: Nov 2, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.